Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
Thirty-four patients with advanced or recurrent mixed mesodermal sarcoma of the uterus were entered in a study of single-agent cisplatin as second-line chemotherapy at a dose of 50 mg/m2 iv every 3 weeks. Twenty-eight of the 34 patients had mixed mesodermal sarcomas and measurable disease and had received one or more courses of the drug. Of these patients, five (18%) had objective response to therapy. Two patients who developed clinical complete response had long progression-free intervals (14 and 16 months) and remained alive at 21 and 36 months after initiation of therapy. Adverse effects were those described in a number of series employing cisplatin and were tolerable. Cisplatin thus appears to have definite activity as a second-line agent in the treatment of mixed mesodermal sarcomas of the uterus.
D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin